A federal judge has put a hold on any further proceedings in the massive, years-long nationwide legal action against Abbvie and other makers of so-called testosterone replacement therapy drugs, saying he wants to give both sides time to complete a potential settlement drug to permanently end the litigation.
Recent News About Levin Papantonio Thomas Mitchell Rafferty & Proctor, PA View More
Verdict much lower, but AbbVie wants $3.2M award tossed in second testosterone class action test trial
North Chicago-based drugmaker AbbVie is resisting what it is calling a jury's “confused and inconsistent” $3.2 million verdict, after the company lost a second trial in Chicago federal court – one in which it was ordered to pay $147 million less than the first trial – over a man’s claims AbbVie allegedly failed to warn its product AndroGel could bring on a heart attack.
About three months after a federal judge threw out a jury’s $150 million verdict and ordered a new trial in the case, a new jury in Chicago has ordered drugmaker Abbvie to pay about $3.2 million to a man who claimed Abbvie’s drug Androgel had caused him to suffer a heart attack.